Affimed raises $14 million from J&J through innovative deal
This article was originally published in Scrip
Executive Summary
Affimed Therapeutics and Johnson & Johnson have entered a collaboration under a novel deal structure that sees Affimed receive cash for an early-stage discovery program, while J&J gets to fund research directly from its balance sheet, a major tax advantage.
You may also be interested in...
Deal Watch: Affimed Teams Up In Immuno-Oncology With Roivant, Artiva
German biotech could realize more than $2bn in earnouts under pact with Roivant. Galmed teams with MyBiotics in attempt to optimize clinical response to its Phase III NASH candidate Aramchol.
UK Reimbursement Decisions Focus Mostly On Cancer
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
Deal Watch: Valeant Sells Off iNova To Finance Debt-Reduction Efforts
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.